NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$12.92

21 May
2025

0.100

OPEN

$13.00

0.78%

HIGH

$13.23

330,689

LOW

$12.84

TARGET
$25.40 96.6% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 111.2 4.3 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx - 10.1% - 96.1% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 298.6 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx111.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx213.2 M
Book Value Per Share xxxxxxxxxxxxxxx286.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.3 M
Net Profit Margin xxxxxxxxxxxxxxx66.61 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx49.92 %
Return on Invested Capital xxxxxxxxxxxxxxx49.92 %
Return on Assets xxxxxxxxxxxxxxx43.20 %
Return on Equity xxxxxxxxxxxxxxx49.92 %
Return on Total Capital xxxxxxxxxxxxxxx61.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx222 M
Price To Book Value xxxxxxxxxxxxxxx4.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx33 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

28/03/2025

1

Buy

$30.80

138.39%

Ord Minnett notes Neuren Pharmaceuticals has added a fifth indication for NNZ-2591, targeting hypoxic-ischemic encephalopathy (HIE), a rare neonatal brain injury with limited treatment options.

NNZ-2591, which has demonstrated a strong safety profile and promising preclinical data, aims to act as a chronic neuroprotective agent in a condition currently only treated with therapeutic hypothermia, explains the broker.

The analyst believes Neuren is well positioned in this space given its expertise in paediatric neurological disorders and views HIE as a favourable clinical setting compared to previous traumatic brain injury studies.

With a potential USD750m addressable market, clinical trials are expected to begin in 2026 following a pre-IND meeting with the FDA later this year.

Buy. Target $30.80
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

13/05/2025

1

Buy

$28.12

117.65%

Canaccord Genuity looked into the 1Q25 Daybue sales from Neuren Pharmaceuticals' marketing partner Acadia's result, noting sales of US$84.6m missed its US$85.1m forecast.

The broker is taking comfort from Acadia's FY25 reiteration of full-year sales guidance, which implies growth in coming quarters. Other relevant metrics were considered solid, including patient growth, expansion in field force, and uptake by community pediatricians.

Also positive was no change indicated in the expected EU approval timing for Daybue. Buy. Target unchanged at $28.12.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 17.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 61.00 cents.

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
Australian Broker Call *Extra* Edition – May 19, 2025

May 19 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 13, 2025

May 13 2025 - Daily Market Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 24-04-25

Apr 24 2025 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Apr 20, 2025

Apr 22 2025 - Daily Market Reports
5
Next Week At A Glance – 22-24 Apr 2025

Apr 17 2025 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
2
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
3
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
4
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
5
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
6
CSL Shares Breaking Free

Jul 23 2024 - Technicals
7
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
8
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
9
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
10
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps